Photo credit:: PATH Malaria Vaccine inniciative

REVOLUTiONiZiNGMALARiA

VACCiNATiON

Company

Researchspin-off of IMM founded in 2013

Faculdade de Medicina da Universidade de Lisboa,

Centro Hospitalar Lisboa-Norte, 1649 – 028

Lisboa, Portugal

MCRC LisboaNIPC: 513226478

Scientific advisory board

Prof. Dr. Robert W. Saurwein

Prof. Chris J. Janse

Prof. Sangeeta N. Bhatia

Dr. Shahid M. KhanDr. Inigo A-Barturen

Business developmentadvisorsFounders

Validation Phase I funding

100 thousand US$(November 2010)

Phase II funding

1.2 million US$ (November 2013)

Supplement to Phase II funding

320 thousand US$(December 2014)

1st IBERIAN project to receive Phase II funding by BMGF

Business development 1st prize in BES innovation contest (December 2013)

80 thousand US$

Honorable mention in 2013 BGI IUL-MIT competition

Finalist of the 6th Universal Biotech innovation Prize

Finalist of the XII EVERIS Foundation entrepreneur award

Stakeholders

Problem

MALARIA 2.5 billion people at risk of contracting malaria

700 thousand deathsevery year

12 billion US$ in lost GDP of endemic countriesNO EFFECTIVE VACCINE

AVAILABLE

Photo credit: Antonio M. Mendes

Most advanced candidate only affords

~36% protection againsta single parasite species

4.5 billion US$ global

market

Humanitarian market:(estimated value: 3 billion US$)

Private market:(estimated value: 700 million US$)

Tourist & military market:(estimated value: 800 million US$)

Market potential

Photo credit: NYtimes

Do not target the most prevalent parasite, P. vivax

Serious safetyconcerns

Vaccine Approaches

Extremely highdosages

WholeorganismvaccinesShown to confer

>90% sterile protection against a

new infection in Phase I/IIa trialsMandatory high biosafety BSL3

production facilities

Photo credit: worldnaturephoto.com

Plasmodiumberghei

Uniqueness

A SAFE & VERSATILEWHOLE-ORGANISM PLATFORM

FOR VACCINATION AGAINSTMULTIPLE HUMAN

PARASITES

PC

T/IB

2013/053050

Phase I/IIa Clinical trials

Submission of authorization request to regulatory authoritiesEfficacy studies in non-human primate modelPharmacological studies in rabbit model

Expected start date: End of 2015

Strategy

Vaccine Clinical Development(Market entry: 2025)

Production & delivery technology(Market entry: 2016)

Production & delivery

Establishment ofcell culture-based production of sporozoites

Development of a vaccine cryopreservation system

Financial returns

2016 onwards:Cryopreservation technology

100 thousandUS$ / year

2020 - 2015:Vaccination platformLicensing / selling

46 million US$

LET’S PUT ANEND TO MALARiA

Photo credit: Antonio M. Mendes

Contact: antoniomendes@medicina.ulisboa.pt